News

Sujay Jadhav, CEO of Verana Health, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), provides an overview of new FDA guidance.

APP13007, according to the company, is the first product developed using Formosa’s proprietary APNT nanoparticle formulation platform.

Professor Gerd Auffarth shares patients’ and colleagues’ responses to a new IOL with a monofocal-like dysphotopsia profile

The contract research organization and technology solution is for the execution of ophthalmology clinical trials.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Rick Lewis, MD, speaks about a non-pharmaceutical approach to treating glaucoma with laser technology

The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in 4Q calendar year 2024. Topline results currently are expected in late 2025

In the case study, a 63-year-old patient presented with severe acute pain in the right eye, which was diagnosed as a pupillary block leading to acute angle closure glaucoma.

BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.

Phase 1 multicentre study data demonstrate early signs of efficacy

MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

The trial is evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia.

The ESCRS Moving Simulator initiative brings surgical training to nations in need

Investigators at the Dean McGee Eye Institute reviewed the accuracy of the tools in measuring 5 vision assessment parameters, including distance visual acuity, near visual acuity, color vision testing, contrast sensitivity, and pupillary distance.

Prevent Blindness is planning a series of events and program partnerships leading up to World Sight Day on Oct. 10, 2024.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss Multiple Sclerosis and its association with reduced choroidal vascularity.

The non-diffractive, aspheric IOLs are the second generation of BVI’s ISOPURE family

Dr Ribeiro, President of the European Society of Cataract and Refractive Surgeons, previewed the 2024 congress

The non-diffractive, aspheric IOLs are the second generation of BVI’s ISOPURE family

The one-time intravitreally delivered gene therapy is for the treatment of retinitis pigmentosa (RP).

A team of researchers at the Center for Regenerative Therapies Dresden of Dresden University of Technology is working to develop a method to replace or regenerate damaged photoreceptor cells in the human retina.

Data from this trial will be reported ahead of AAO 2024 in Chicago, Illinois.

This certification covers AI based regulatory requirements for the company's platform for AI imaging and diagnostic tools.

A case report demonstrates independent effect of GLP-1 receptor agonist

Data from this trial will be reported ahead of AAO 2024 in Chicago, Illinois.

The 4-year study is set to involve up to 20 patients and is a part of the Foundation's Uni-Rare natural history study.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.